Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02924402 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
A Phase 1 study of Chronic Lymphocytic Leukemia and B Cell Non-Hodgkin's Lymphoma, sponsored by Xencor.
- Completed
- Registry status
- Phase 1
- Development phase
- 154
- Enrollment target
- 20
- Study locations
NCT02924402 is a Phase 1 study of Chronic Lymphocytic Leukemia and B Cell Non-Hodgkin's Lymphoma that has completed, run by Xencor. The registered enrollment target is 154 participants, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT02924402, a Phase 1 study of Chronic Lymphocytic Leukemia and B Cell Non-Hodgkin's Lymphoma, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 154 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).
Conditions Studied
Interventions
- BIOLOGICAL XmAb13676
Study Locations (20)
Other
- Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest - Bordeaux
- Hopital Henri Mondor - Créteil
- Institut Paoli Calmette Dpt of Oncology/Hematology - Marseille
- Chu Montpellier, Hematologie Clinique St. Eloi - Montpellier
- CHU de Nantes - Nantes
- Centre Antoine Lacassagne - Nice
- CHU Haut-Leveque, Service d'Hematologie Clinique et Therapie Cellulaire - Pessac
- Centre Hospitalier Lyon-Sud, Service d'Hematologie - Pierre-Bénite
- Centre Henri Becquerel - Rouen
- Institut Universitaire du Cancer Toulouse Oncopole - Toulouse
California
- Moores UC San Diego Cancer Center - La Jolla
Florida
- Mayo Clinic - Jacksonville
Georgia
- Northside Hospital - Atlanta
Illinois
- The University of Chicago Medicine - Chicago
Michigan
- University of Michigan - Ann Arbor
Ohio
- The Ohio State University Wexner Medical Center and James Cancer Hospital - Columbus
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2016-10 |
| Est. Completion | 2024-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02924402
The ClinicalTrials.gov registry entry for NCT02924402 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (15% lower). The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which XmAb13676 is the first listed.
NCT02924402 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02924402 about?
NCT02924402 is a clinical study titled "Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies". The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).
What is the current status of trial NCT02924402?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 154 participants. The study started on 2016-10. Estimated completion is 2024-04.
What conditions does trial NCT02924402 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, B Cell Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT02924402?
The interventions under investigation include: XmAb13676 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02924402?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02924402 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
RECRUITING · Phase 1
-
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
RECRUITING · Phase 1
-
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
RECRUITING · Phase 1
-
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
RECRUITING · Phase 1
-
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
Explore more on PlainTrial
Chronic Lymphocytic Leukemia
All registered trials for this condition
B Cell Non-Hodgkin's Lymphoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.